Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692.
OBJECTIVE
Integrin scintimammography with NC100692 and a dedicated gamma-camera, LumaGEM, based on semi-conductor technology, was performed to investigate the detection ability of this combination in breast cancer.


METHODS
Eight patients with a high suspicion of breast cancer were administered 600-750 MBq (99m)Tc-labelled NC100629. Two acquisitions using a cranio-caudal and a lateral view were used, with moderate compression of the breast.


RESULTS
LumaGEM scintigraphy revealed 9 of 11 malignancies, sized 6-20 mm. Two lesions in patients with multicentric disease were not diagnosed, one of which measured only 2.5 mm. In one patient, the procedure was inconclusive, due to major breast hypertrophy.


CONCLUSIONS
The combined use of NC100629 and a dedicated gamma-camera for breast imaging was highly effective in diagnosing breast cancer.
Bach-Gansmo
Tore
T
Department of Nuclear Medicine, Institute for Surgical Sciences, University of Bergen, Bergen, Norway. ingolv.tore.bach-gansmo@helse-bergen.no
Bogsrud
Trond V
TV
Skretting
Arne
A
D000368:Aged; D001940:Breast / Q000000981:diagnostic imaging*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D015902:Gamma Cameras; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008327:Mammography; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging; D015609:Organotechnetium Compounds / Q000378:metabolism; D010456:Peptides, Cyclic / Q000378:metabolism; D011877:Radionuclide Imaging
D039302:Integrin alphaVbeta3; D015609:Organotechnetium Compounds; D010456:Peptides, Cyclic; C514230:technetium 99m NC 100692